Michael David Garrison Sells 1,185 Shares of Becton, Dickinson and Company (NYSE:BDX) Stock

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael David Garrison sold 1,185 shares of the company's stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares of the company's stock, valued at approximately $881,077.23. The trade was a 19.52% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock traded up $1.89 during midday trading on Friday, reaching $185.52. 1,875,850 shares of the stock traded hands, compared to its average volume of 2,931,804. The stock has a market cap of $53.17 billion, a P/E ratio of 35.40, a PEG ratio of 1.39 and a beta of 0.25. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The stock's fifty day moving average is $174.31 and its 200-day moving average is $202.75. The company has a quick ratio of 0.64, a current ratio of 1.13 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.07. The business had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a return on equity of 15.99% and a net margin of 7.28%. The company's revenue for the quarter was up 4.5% on a year-over-year basis. During the same period last year, the company earned $3.17 EPS. As a group, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be paid a $1.04 dividend. This represents a $4.16 annualized dividend and a dividend yield of 2.24%. The ex-dividend date is Monday, September 8th. Becton, Dickinson and Company's payout ratio is 79.39%.

Institutional Investors Weigh In On Becton, Dickinson and Company

Several institutional investors have recently modified their holdings of BDX. Vanguard Group Inc. raised its holdings in shares of Becton, Dickinson and Company by 4.7% in the first quarter. Vanguard Group Inc. now owns 28,002,802 shares of the medical instruments supplier's stock worth $6,414,322,000 after buying an additional 1,259,750 shares during the period. T. Rowe Price Investment Management Inc. raised its holdings in shares of Becton, Dickinson and Company by 3.7% in the first quarter. T. Rowe Price Investment Management Inc. now owns 12,575,351 shares of the medical instruments supplier's stock worth $2,880,510,000 after buying an additional 448,644 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Becton, Dickinson and Company by 10.8% in the first quarter. Massachusetts Financial Services Co. MA now owns 6,843,856 shares of the medical instruments supplier's stock worth $1,567,654,000 after buying an additional 667,957 shares during the period. Geode Capital Management LLC raised its holdings in shares of Becton, Dickinson and Company by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 6,351,537 shares of the medical instruments supplier's stock worth $1,437,161,000 after buying an additional 66,024 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in shares of Becton, Dickinson and Company by 7.6% in the first quarter. JPMorgan Chase & Co. now owns 4,420,887 shares of the medical instruments supplier's stock worth $1,012,649,000 after buying an additional 312,124 shares during the period. 86.97% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Raymond James Financial lowered Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a research note on Friday, May 2nd. Wall Street Zen lowered Becton, Dickinson and Company from a "buy" rating to a "hold" rating in a research note on Friday, May 2nd. Morgan Stanley dropped their price objective on Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating for the company in a research note on Tuesday, May 6th. Piper Sandler lowered Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and dropped their price objective for the stock from $260.00 to $185.00 in a research note on Friday, May 2nd. Finally, Citigroup lowered Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and dropped their price objective for the stock from $217.00 to $185.00 in a research note on Thursday, May 22nd. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $219.22.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.